September 9, 2019 / 2:17 PM / 6 days ago

BRIEF-Molecular Partners Says U.S. Marketing Application Accepted For Abicipar Pegol In Patients With Macular Degeneration

Sept 9 (Reuters) - Molecular Partners AG:

* ALLERGAN AND MOLECULAR PARTNERS ANNOUNCE ACCEPTANCE OF U.S. FDA BIOLOGICS LICENSE APPLICATION AND VALIDATION OF EMA MARKETING AUTHORISATION FOR ABICIPAR PEGOL IN PATIENTS WITH NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION

* MOLECULAR PARTNERS AG - FDA IS EXPECTED TO TAKE ACTION ON BLA MID-2020

* MOLECULAR PARTNERS AG - DECISION FROM EUROPEAN COMMISSION IS EXPECTED IN SECOND HALF OF 2020. Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below